Thu, Feb 25, 2021 11:00 AM – 12:00 PM EST Register Accessibility to real-world data (RWD) and advances in artificial intelligence (AI) driven models and technologies make a powerful combination in advancing research and development efforts. So how do we use these new tools to tackle the challenges in developing and launching new treatments for[…]
BOSTON, Jan. 28, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), outcomes and technology company with a focus on chronic diseases, today announced the launch of an expanded Heart Failure registry. Heart Failure (HF) is considered a growing healthcare epidemic and is associated with significant mortality, morbidity and resource utilization. In the United States, HF is estimated to[…]
BOSTON, Dec. 8, 2020 /PRNewswire/ — OM1, a leading real-world, data, outcomes and technology company with a focus on chronic diseases, today announced the expansion of its Giant Cell Arteritis (GCA) registry. GCA, also known as temporal arteritis, is a chronic inflammatory artery disease that causes head pain, joint pain, vision problems, and fever. GCA affects approximately 230,000 Americans,[…]
Tues. January 26, 2021 2:00-3:00 PM Register Real-world data (RWD) is playing an increasing role in health care decisions, especially with cardiovascular conditions such as heart failure where risk of mortality is high and comorbidities, varying symptom presentation, and disease progression drastically determine treatment pathways and outcomes. Join OM1’s Chief Medical Officer Dr. Gary Curhan[…]
October 12, 2020 – MedTech by Richard Gliklich, MD, CEO of OM1 and Michelle Leavy, MPH, Head of Health Policy at OM1 Read the full article Interest in real-world data (RWD) and real-world evidence (RWE) has increased rapidly since the passage of the 21st Century Cures Act in late 2016. Use of RWD and RWE for[…]
